logo

Beigene (BGNE)



Trade BGNE now with
  Date
  Headline
9/20/2018 11:50:47 PM BeiGene Presents Results On Anti-PD-1 Antibody Tislelizumab In Chinese Patients With Lung Cancers
9/20/2018 4:49:25 AM BeiGene Presents Preliminary Results On Anti-PD-1 Antibody Tislelizumab
9/6/2018 6:02:33 AM BeiGene, SpringWorks Therapeutics Enter Into Global Clinical Collaboration To Evaluate Targeted Combination Therapy
8/31/2018 6:01:23 AM BeiGene Announces Acceptance Of NDA For Anti-PD-1 Antibody Tislelizumab In Hodgkin’s Lymphoma In China
8/9/2018 5:07:14 AM BeiGene Q2 Net Loss $156.89 Mln Or $2.92/ADS Vs Loss $60.55 Mln Or $1.52/ADS Last Year
8/9/2018 5:06:13 AM BeiGene Initiates New Phase 3 Trial Of Anti-PD-1 Antibody Tislelizumab Combined With Chemotherapy
7/24/2018 7:10:01 AM BeiGene Begins Global Phase 3 Trial Of PARP Inhibitor Pamiparib In Patients With Advanced Gastric Cancer
7/22/2018 4:32:02 PM BeiGene Plan To Pursue Accelerated Approval In US Of BTK Inhibitor Zanubrutinib In Waldenström Macroglobulinemia
7/22/2018 4:31:38 PM BeiGene Releases Results Of Pivotal Trial In China For Anti-PD-1 Antibody Tislelizumab In Hodgkin’s Lymphoma
7/20/2018 4:51:29 AM BeiGene Attends Hearing Before The Listing Committee Of The Stock Exchange Of Hong Kong Limited
7/3/2018 4:06:29 PM BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
6/15/2018 2:26:15 AM BeiGene Provides Development Update And Presents Clinical Data On Zanubrutinib
5/17/2018 7:07:25 AM BeiGene Begins Phase 3 Trial Of Pamiparib As Maintenance Therapy In Chinese Patients With Ovarian Cancer
4/16/2018 7:05:11 AM BeiGene Begins Phase 2 Trial Of Tislelizumab In Relapsed Or Refractory Mature T-and NK-Cell Lymphomas
4/10/2018 7:04:37 AM BeiGene Initiates Global Phase 2 Trial Of Anti-PD-1 Antibody Tislelizumab For HCC Or Liver Cancer
2/5/2018 6:17:16 PM BeiGene Reports Commercial Availability Of VIDAZA (Azacitidine For Injection) In China